Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 8/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | MC3R | P41968 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.48 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4453355 | 0.99 | ADORA2B (0.49) | ADORA2BACHEPIK3CDPOLBADORA3 | |
| SCHEMBL122001 | 0.98 | ADORA2B (0.48) | ADORA2BACHEPIK3CDPOLBADORA3 | |
| SCHEMBL5430755 | 0.98 | ADORA2B (0.48) | ADORA2BACHEPIK3CDPOLBADORA3 | |
| Caffeine SCHEMBL667174 | 0.80 | ADORA2B (0.62) | ADORA2BACHEPIK3CDPOLBADORA3 | |
| Caffeine SCHEMBL2468803 | 0.78 | ADORA2B (0.59) | ADORA2BACHEPIK3CDPOLBADORA3 | |
| SCHEMBL1764613 | 0.77 | ADORA2B (0.61) | ADORA2BACHEPIK3CDPOLBADORA3 | |
| SCHEMBL3119654 | 0.76 | ADORA2B (0.60) | ADORA2BACHEPIK3CDPOLBADORA3 | |
| Caffeine SCHEMBL7614321 | 0.73 | ADORA2B (0.53) | ADORA2BACHEPIK3CDPOLBADORA3 | |
| SCHEMBL684044 | 0.71 | ADORA2B (0.49) | ADORA2BACHEPIK3CDPOLBADORA3 | |
| Caffeine SCHEMBL10638955 | 0.71 | ADORA2B (0.73) | ADORA2BACHEPIK3CDPOLBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 727 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160008328-A1 | Stable Pharmaceutical Package Comprising Azilsartan Medoxomil | CADILA HEALTHCARE LIMITED (IN) | 2016-01-14 | — | — | US | claimed |
| US-20040034042-A1 | Preservative composition | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-19 | — | — | US | claimed |
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4735456-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4665730-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-1077957-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000000212-A1 | PROMOTING NITRIC OXIDE AND CYCLIC GMP ACTIVITY | NUTRACORP SCIENTIFIC, INC. (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999034675-A1 | PROMOTING MOBILIZATION AND CATABOLISM OF LIPIDS | NUTRACORP SCIENTIFIC, INC. (US) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999024040-A1 | PROMOTING HORMONE PRODUCTION | NUTRACORP SCIENTIFIC, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0912181-A1 | APPETITE SUPPRESSION | Nutracorp Scientific, Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1999008681-A1 | INDUCING NEUROTRANSMITTER AND NEUROPEPTIDE ACTIVITY | NUTRACORP SCIENTIFIC, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1998002165-A1 | APPETITE SUPPRESSION | NUTRACORP SCIENTIFIC, INC. (US) | 1998-01-22 | — | — | WO | disclosed |
| US-4198507-A | MUSCLE RELAXANTS, DIURETICS, ANALGESICS | HOFFMANN-LA ROCHE INC. (US) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | NPY1R, CALCRL, SCTR | ADORA2B 625/4885ACHE 2235/4885PIK3CD 3412/4885 |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GLP1R, NPY1R, NPY2R | ADORA2B 628/4885ACHE 3336/4885PIK3CD 3493/4885 |
| US-20040034042-A1 | Preservative composition | XDH, XPA, SORBS1 | ADORA2B 559/4885ACHE 908/4885PIK3CD 3463/4885 |
| US-20160008328-A1 | Stable Pharmaceutical Package Comprising Azilsartan Medoxomil | REN, AVPR2, QDPR | ADORA2B 1107/4885ACHE 4090/4885PIK3CD 3640/4885 |
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | ADORA2B 930/4885ACHE 3644/4885PIK3CD 3140/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | ADORA2B 1264/4885ACHE 3252/4885PIK3CD 2015/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | ADORA2B 557/4885ACHE 2232/4885PIK3CD 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.